[9]. Zhou C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase ...
TROPION-Lung01(TL01)研究是ADC药物在肺癌领域首个且目前唯一获得阳性结果的III期临床试验,本次大会进一步详细公布了TL01研究非鳞状(Nonsquamous,NSQ)非小细胞肺癌(NSCLC)亚组结果(摘要号:59P)[1],研究结果显示,Dato-DXd取得明显无进...
Moreover, the MET status in non-squamous NSCLC tumor areas showed highly heterogeneous among various histotypes, hindering the adequate patient selection for MET-targeted therapies[12]. The intratumor heterogeneity referred to subclonal diversities of tumor cells was observed in this study. The ...
9.Herbst RS,Lopes G,Kowalski DM,et al.LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042[J].Ann Oncol,2019,30(Suppl 11):xi63-64. 10.Gadgeel S,Rodríguez-Abreu D,...
近年来,随着肺癌的发病率逐渐上升,免疫治疗在肺癌治疗中的作用日趋重要。目前,免疫治疗已改变晚期非小细胞肺癌(NSCLC)的治疗格局。在日前落幕的世界顶级肿瘤学术会议——美国临床肿瘤学会(ASCO)上,多项NSCLC免疫治疗研究进行更新,“医学界肿瘤频道”特整理其精华内容,为大家带来最新前沿进展。
[20]LuS, WuL, JianH, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase ...
Vadimezan is safe and active in both squamous and non-squamous NSCLCAn abstract is unavailable.doi:10.1097/01.OTU.0000398562.48570.81TumaRabiya SOncology Times Uk
探索靶向联合治疗的生物标记物将有助于进一步的精准治疗,多项回顾性研究显示存在共突变患者靶向单药治疗的效果欠佳,目前评估靶向联合治疗在共突变人群疗效的多个III期研究正在进行,例如一项III期研究评估奥希替尼 vs 奥希替尼+培美曲塞+卡铂一线治疗EGFR、TP53共突变晚期NSCLC的疗效和安全性(NCT04695925),一项III期研究评...
[5] Hui Yu, Ping Chen, Liangping Xia, el al. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer. Journal for Immunotherapy of Cancer. 2021 Nov;9(11):e003431. ...
[20]LuS, WuL, JianH, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase ...